183 related articles for article (PubMed ID: 34585443)
1. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
Black DM; Reid IR; Napoli N; Ewing SK; Shiraki M; Nakamura T; Takeuchi Y; Schafer AL; Kim TY; Cauley JA
J Bone Miner Res; 2022 Jan; 37(1):21-28. PubMed ID: 34585443
[TBL] [Abstract][Full Text] [Related]
2. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
5. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
[TBL] [Abstract][Full Text] [Related]
6. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM; Reid IR; Cauley JA; Cosman F; Leung PC; Lakatos P; Lippuner K; Cummings SR; Hue TF; Mukhopadhyay A; Tan M; Aftring RP; Eastell R
J Bone Miner Res; 2015 May; 30(5):934-44. PubMed ID: 25545380
[TBL] [Abstract][Full Text] [Related]
7. The role of zoledronic acid in the management of osteoporosis.
Maricic M
Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
[TBL] [Abstract][Full Text] [Related]
8. The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients.
Lu K; Wu YM; Shi Q; Gong YQ; Zhang T; Li C
Osteoporos Int; 2023 Sep; 34(9):1613-1623. PubMed ID: 37247006
[TBL] [Abstract][Full Text] [Related]
9. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
[TBL] [Abstract][Full Text] [Related]
10. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Adachi JD; Lyles KW; Colón-Emeric CS; Boonen S; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Bucci-Rechtweg C; Su G; Eriksen EF; Magaziner JS
Osteoporos Int; 2011 Sep; 22(9):2539-49. PubMed ID: 21249332
[TBL] [Abstract][Full Text] [Related]
12. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
[TBL] [Abstract][Full Text] [Related]
13. Association between timing of zoledronic acid infusion and hip fracture healing.
Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
[TBL] [Abstract][Full Text] [Related]
14. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
[TBL] [Abstract][Full Text] [Related]
15. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
Chen FP; Fu TS; Lin YC; Lin YJ
Osteoporos Int; 2021 Apr; 32(4):663-670. PubMed ID: 33113007
[TBL] [Abstract][Full Text] [Related]
16. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
17. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
Billington EO; Horne A; Gamble GD; Maslowski K; House M; Reid IR
Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
[TBL] [Abstract][Full Text] [Related]
18. Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.
Magaziner JS; Orwig DL; Lyles KW; Nordsletten L; Boonen S; Adachi JD; Recknor C; Colón-Emeric CS; Mesenbrink P; Bucci-Rechtweg C; Su G; Johnson R; Pieper CF
J Bone Miner Res; 2014 Dec; 29(12):2545-51. PubMed ID: 24839241
[TBL] [Abstract][Full Text] [Related]
19. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
[TBL] [Abstract][Full Text] [Related]
20. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.
Shiraki M; Kuroda T; Takeuchi Y; Sugimoto T; Tanaka S; Suzuki H; Hiraishi K; Nakamura T
Calcif Tissue Int; 2021 Dec; 109(6):666-674. PubMed ID: 34247263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
